首页> 外文期刊>Oncology reports >Risk assessment model constructed by differentially expressed lncRNAs for the prognosis of glioma
【24h】

Risk assessment model constructed by differentially expressed lncRNAs for the prognosis of glioma

机译:差异表达LNCRNA构建的风险评估模型,用于胶质瘤预后

获取原文
获取原文并翻译 | 示例
           

摘要

A risk assessment model was constructed using differentially expressed long non-coding (lnc)RNAs for the prognosis of glioma. Transcriptome sequencing of the lncRNAs and mRNAs from glioma samples were obtained from the TCGA database. The samples were divided into bad and good prognosis groups based on survival time, then differently expressed lncRNAs between these two groups were screened using DEseq and edgeR packages. Multivariate Cox regression analysis was performed to establish a risk assessment system according to the weighted regression coefficient of lncRNA expression. Survival analysis and receiver operating characteristic curve were conducted for the risk assessment model. Furthermore, the co-expression network of the screened lncRNAs was constructed, followed by the functional enrichment analysis for associated genes. A total of 117 lncRNAs were screened using edgeR and DEseq packages. Among all differently expressed lncRNAs, five lncRNAs (RP3-503A6, LINC00940, RP11-453M23, AC009411 and CDRT7) were identified to establish the risk assessment model. The risk assessment model demonstrated a good prognostic function with high area under the curve values in the training, validation and entire sets. The risk score was certified as an independent prognostic factor for gliomas. Multiple genes were screened to be co-expressed with these five lncRNAs. Functional enrichment analysis demonstrated that they were involved in cytoskeleton, adhesion and Janus kinase/signal transducer and activator of transcription signaling pathway-associated processes. The present study established a risk assessment model integrating five significantly different expressed lncRNAs, which may help to assess the prognosis of patients with glioma with increased accuracy.
机译:使用差异表达的长非编码(LNC)RNA来构建风险评估模型,用于胶质瘤的预后。从TCGA数据库中获得来自胶质瘤样品的LNCRNA和MRNA的转录组测序。将样品分为基于存活时间的坏和良好的预后组,然后使用Deseq和Edger封装筛选这两组之间的不同表达的LNCRNA。进行多元COX回归分析,以根据LNCRNA表达的加权回归系数建立风险评估系统。对风险评估模型进行了生存分析和接收机操作特征曲线。此外,构建了筛选的LNCRNA的共表达网络,然后进行了相关基因的功能性富集分析。使用Edger和Deseq封装筛选总共117个LNCRNA。在所有不同表达的LNCRNA中,确定了五个LNCRNA(RP3-503A6,LINC00940,RP11-453M23,AC009411和CDRT7)以建立风险评估模型。风险评估模型在训练,验证和整套中,在曲线值下具有良好的预后功能。风险评分被认证为Gliomas的独立预后因素。筛选多基因与这五种LNCRNA共同表达。功能性富集分析证明它们参与了细胞骨架,粘附和Janus激酶/信号传感器和转录信号通路相关过程的活化剂。本研究建立了一项风险评估模型,其含有五种显着不同的表达的LNCRNA,这可能有助于评估胶质瘤患者的预后,提高精度。

著录项

  • 来源
    《Oncology reports》 |2018年第5期|共10页
  • 作者单位

    Sichuan Univ West China Hosp Dept Crit Care Med 37 Guo Xue Xiang Chengdu 610041 Sichuan;

    Sichuan Univ West China Hosp Dept Crit Care Med 37 Guo Xue Xiang Chengdu 610041 Sichuan;

    Sichuan Univ West China Hosp Dept Crit Care Med 37 Guo Xue Xiang Chengdu 610041 Sichuan;

    Sichuan Univ West China Hosp Dept Crit Care Med 37 Guo Xue Xiang Chengdu 610041 Sichuan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    glioma; risk assessment model; prognosis;

    机译:胶质瘤;风险评估模型;预后;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号